NEW YORK, June 29, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that its response to the Department of Health and Human Services’ (HHS) request for proposal for 1.7 million courses of a smallpox antiviral for the Strategic National Stockpile was found to be in the competitive range.
